

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
www.sunpharma.com
CIN : L24230GJ1993PLC019050



November 22, 2016

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
NSE Code – SUNPHARMA

BSE Ltd,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.
BSE Code– 524715

Sub: Update on Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs,

Further to our letter dated December 23, 2016 under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of which is attached herewith as Annexure , regarding acquisition of 13,000,000 Series B Preferred Stock of scPharmaceuticals Inc., by one of the wholly owned subsidiaries of the Company, we hereby inform you the following :

- 1) The aforesaid 13,000,000 Series B Preferred Stock of scPharmaceuticals Inc., have been converted into 1,810,536 shares of common stock (representing approximately 10.3% of the total shares outstanding par value \$0.0001 each), on November 21, 2017. Another wholly owned subsidiary of the Company has purchased 357,143 shares of common stock, par value \$0.0001 each, at a price of USD 14 per share, of scPharmaceuticals Inc. amounting to about USD 5 million (USD Five Million) by way of allotment on November 21, 2017 in the Initial Public Offering (“IPO”) by scPharmaceuticals Inc., which are equivalent to 5.58% of the total shares offered in IPO.
- 2) Post the conversion, the aforesaid purchase of shares and the aforesaid IPO, the total stake held by our subsidiaries in scPharmaceuticals Inc., is reduced from 14.58% (basis fully diluted equity stake on conversion) to 12.31% (based on the fully diluted number of shares of common stock after the IPO however before the underwriters’ exercise of any of the overallotment).

This is for your information and record.

Yours faithfully,

For Sun Pharmaceutical Industries Limited,

Ashok I Bhuta
Compliance Officer

Enclosure: As above



Registered Office : SPARC, Tandalja, Vadodara – 390 020. India

Registered Office : SPARC, Tandalja, Vadodara - 390 020, Gujarat. INDIA.

Annexure A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

<p>a) Name of the target entity, details in brief such as size, turnover etc.;</p>	<p>i) Name of the Target : “scPharmaceuticals Inc.” (Target)</p> <p>ii) Details of the Target: scPharmaceuticals Inc., is a United States pharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery.</p> <p>2015 Sales: NIL</p>
<p>b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms-length”;</p>	<p>scPharmaceuticals Inc., is an independent company and the promoter/ promoter group/ group companies of Sun Pharmaceutical Industries Limited have no interest in the Target so the acquisition would not fall within related party transaction(s).</p>
<p>c) Industry to which the entity being acquired belongs;</p>	<p>Pharmaceuticals</p>
<p>d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);</p>	<p>Investment in Pharmaceutical Company</p>
<p>e) Brief details of any governmental or regulatory approvals required for the acquisition;</p>	<p>None</p>
<p>f) Indicative time period for completion of the acquisition;</p>	<p>Completed</p>
<p>g) Nature of consideration - whether cash consideration or share swap and details of the same;</p>	<p>Cash consideration.</p>

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E)
Mumbai – 400 063. Maharashtra, INDIA
Tel : (91-22) 4324 4324
Fax : (91-22) 4324 4343
www.sunpharma.com
CIN: L24230GJ1993PLC019050



h) Cost of acquisition or the price at which the shares are acquired;	Consideration for Series B Preferred Stock acquired is USD 13 Million.
i) Percentage of shareholding / control acquired and / or number of shares acquired;	13,000,000 Series B Preferred Stock of scPharmaceuticals Inc. (equivalent to 14.58% fully diluted equity stake on conversion), by way of allotment
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Brief background:</p> <p>scPharmaceuticals Inc., incorporated in 2014, is a United States pharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Based on widely used generic drugs that currently require intravenous or intramuscular injections, scPharmaceuticals' proprietary and innovative products will be administered subcutaneously via the sc2Wear™ Infusor. This subcutaneous administration avoids material risks and costs associated with the current delivery options. It's lead products are the first subcutaneous formulations of furosemide (the most widely used parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used parenteral antibiotic outside the hospital setting). (http://www.scpharmaceuticals.com/)</p> <p>2015 Sales: NIL</p> <p>2014 Sales: NIL</p>